Loading
Obesity / Healthy Participants / AZD1043 · Phase 1 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 study registration for AZD1043, a novel investigational drug, in healthy adults with overweight and/or obesity. The study is currently recruiting and aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics over single and multiple ascending doses. No efficacy data, safety results, or outcome analyses are available in this registry record.
Phase 1, Interventional, Randomized, Sequential, Triple masking, Treatment purpose. Healthy Participants, Obesity; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Part A1 (Global SAD): Cohort 1 - AZD1043 (Dose 1); Part A1 (Global SAD): Cohort 2 - AZD1043 (Dose 2); Part A1 (Global SAD): Cohort 3 - AZD1043 (Dose 3); Part A1 (Global SAD): Cohort 4 - AZD1043 (Dose 4); Part A1 (Global SAD): Cohort 5 - AZ…. Compared with: Placebo. n = 104. 3 sites: United States, United Kingdom.
This is a Phase 1 study registration for AZD1043, a novel investigational drug, in healthy adults with overweight and/or obesity. The study is currently recruiting and aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics over single and multiple ascending doses. No efficacy data, safety results, or outcome analyses are available in this registry record.
This is a registry record only; no safety or efficacy results are reported
This is a first-in-human study with no results reported; it is not yet appropriate for clinical decision-making. Readers should monitor for completion and publication of safety and pharmacology data before considering any progression to later-phase clinical trials.
This is a Phase 1 first-in-human study of a novel drug in healthy volunteers; no results are posted in this registry record, and the study is still recruiting.
As stated by the source record.
Quoted from the source exactly as published.
This is a first-in-human study with no results reported; it is not yet appropriate for clinical decision-making. Readers should monitor for completion and publication of safety and pharmacology data before considering any progression to later-phase clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07511205). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 104 participants (ESTIMATED). Conditions: Healthy Participants, Obesity. Interventions: DRUG: AZD1043; OTHER: Placebo. Primary outcome measures: Number of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs) , Part A (SAD): From Day-35 to Day 253; Part B (MAD): From Day 1 to Day 253. Brief summary: The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.